



## Clinical trial results:

### An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias

#### Summary

EudraCT number	2011-004378-27
Trial protocol	ES HU DE IT SK AT
Global end of trial date	04 November 2013

#### Results information

Result version number	v1 (current)
This version publication date	13 July 2016
First version publication date	01 August 2015

#### Trial information

##### Trial identification

Sponsor protocol code	CAFQ056A2299
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01491932
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002 , Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111 ,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111 ,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	04 November 2013
Is this the analysis of the primary completion data?	No

---

Global end of trial reached?	Yes
Global end of trial date	04 November 2013
Was the trial ended prematurely?	Yes

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To evaluate the long-term safety and tolerability of AFQ056 in patients with PD-LID as assessed by  
•Incidence and severity of adverse events and serious adverse events •Changes in vital signs, laboratory assessments, and ECGs •Changes in underlying symptoms of PD as measured by the UPDRS (Unified Parkinson's Disease Rating Scale) part III (Motor Examination) and AEs potentially related to an exacerbation of the movement disorder of PD

---

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

---

Background therapy: -

---

Evidence for comparator: -

---

Actual start date of recruitment	09 March 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Canada: 5
Country: Number of subjects enrolled	Slovakia: 4
Country: Number of subjects enrolled	Spain: 32
Country: Number of subjects enrolled	Austria: 4
Country: Number of subjects enrolled	France: 11
Country: Number of subjects enrolled	Germany: 33
Country: Number of subjects enrolled	Hungary: 5
Country: Number of subjects enrolled	Italy: 28
Country: Number of subjects enrolled	United States: 5
Country: Number of subjects enrolled	Switzerland: 2
Worldwide total number of subjects	129
EEA total number of subjects	117

---

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	53
From 65 to 84 years	76
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Patients who completed a previous core study and met the inclusion/exclusion criteria entered the open-label treatment phase.

### Pre-assignment

Screening details:

Patients who entered into this open-label treatment study within one week of completion of the last entered the study directly and the screening and baseline visit was performed on the same day. If more than one week after completion of the last visit of the core study; patients underwent a separate screening and baseline visit .

### Period 1

Period 1 title	Open-label Treatment Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	AFQ056 25 mg b.i.d.

Arm description:

AFQ056 25 mg for oral administration

Arm type	Experimental
Investigational medicinal product name	AFQ056
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

The investigational drug, AFQ056, was provided as hard gelatin capsules. All patients took one capsule in the morning and in the evening.

<b>Arm title</b>	AFQ056 50 mg b.i.d.
------------------	---------------------

Arm description:

AFQ056 50 mg for oral administration

Arm type	Experimental
Investigational medicinal product name	AFQ056
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

The investigational drug, AFQ056, was provided as hard gelatin capsules. All patients took one capsule in the morning and in the evening.

<b>Arm title</b>	AFQ056 75 mg b.i.d.
------------------	---------------------

Arm description:

AFQ056 75 mg for oral administration

Arm type	Experimental
----------	--------------

Investigational medicinal product name	AFQ056
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

The investigational drug, AFQ056, was provided as hard gelatin capsules. All patients took one capsule in the morning and in the evening.

<b>Arm title</b>	AFQ056 100 mg b.i.d.
------------------	----------------------

Arm description:

AFQ056 100 mg for oral administration

Arm type	Experimental
Investigational medicinal product name	AFQ056
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

The investigational drug, AFQ056, was provided as hard gelatin capsules. All patients took one capsule in the morning and in the evening.

<b>Number of subjects in period 1</b>	AFQ056 25 mg b.i.d.	AFQ056 50 mg b.i.d.	AFQ056 75 mg b.i.d.
Started	20	20	20
Completed	0	0	0
Not completed	20	20	20
Physician decision	1	1	-
Study Terminated By Sponsor	10	10	17
Adverse event, non-fatal	5	7	2
Subject/Guardian Decision	2	1	-
'New Therapy For Study Indication '	1	-	-
Lost to follow-up	1	-	1
Protocol deviation	-	1	-
Lack of efficacy	-	-	-

<b>Number of subjects in period 1</b>	AFQ056 100 mg b.i.d.
Started	69
Completed	0
Not completed	69
Physician decision	1
Study Terminated By Sponsor	47
Adverse event, non-fatal	13
Subject/Guardian Decision	1

'New Therapy For Study Indication '	-
Lost to follow-up	-
Protocol deviation	-
Lack of efficacy	7

## Baseline characteristics

### Reporting groups

Reporting group title	AFQ056 25 mg b.i.d.
Reporting group description: AFQ056 25 mg for oral administration	
Reporting group title	AFQ056 50 mg b.i.d.
Reporting group description: AFQ056 50 mg for oral administration	
Reporting group title	AFQ056 75 mg b.i.d.
Reporting group description: AFQ056 75 mg for oral administration	
Reporting group title	AFQ056 100 mg b.i.d.
Reporting group description: AFQ056 100 mg for oral administration	

Reporting group values	AFQ056 25 mg b.i.d.	AFQ056 50 mg b.i.d.	AFQ056 75 mg b.i.d.
Number of subjects	20	20	20
Age categorical Units: Subjects			
Adults (18-64 years)			
From 65-84 years			
Age continuous Units: years			
arithmetic mean	65.9	67.5	62.9
standard deviation	± 8.69	± 7.93	± 8.64
Gender categorical Units: Subjects			
Female	7	13	6
Male	13	7	14

Reporting group values	AFQ056 100 mg b.i.d.	Total	
Number of subjects	69	129	
Age categorical Units: Subjects			
Adults (18-64 years)		0	
From 65-84 years		0	
Age continuous Units: years			
arithmetic mean	65.9		
standard deviation	± 8.79	-	
Gender categorical Units: Subjects			
Female	29	55	
Male	40	74	

## End points

### End points reporting groups

Reporting group title	AFQ056 25 mg b.i.d.
Reporting group description: AFQ056 25 mg for oral administration	
Reporting group title	AFQ056 50 mg b.i.d.
Reporting group description: AFQ056 50 mg for oral administration	
Reporting group title	AFQ056 75 mg b.i.d.
Reporting group description: AFQ056 75 mg for oral administration	
Reporting group title	AFQ056 100 mg b.i.d.
Reporting group description: AFQ056 100 mg for oral administration	
Subject analysis set title	Full Analysis Set (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: The FAS included all patients who received at least one dose of study medication during this open-label study.	
Subject analysis set title	Safety Set (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: The SS consisted of all patients who received at least one dose of open-label study drug during this open-label study and who had at least one post- baseline safety assessment.	

### Primary: Percentage of patients with at least one treatment emergent AEs

End point title	Percentage of patients with at least one treatment emergent AEs <sup>[1]</sup>
End point description: Treatment-emergent adverse event (TEAE) was defined as any AE newly occurred or worsened in severity after starting study drug during the open-label treatment phase.	
End point type	Primary
End point timeframe: From Baseline for duration of study until early termination (04Nov2013)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No additional statistical analyses have been performed for this primary end point.

End point values	AFQ056 25 mg b.i.d.	AFQ056 50 mg b.i.d.	AFQ056 75 mg b.i.d.	AFQ056 100 mg b.i.d.
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	20	20	69
Units: Percentage of participants				
number (not applicable)	90	95	100	72.5

## Statistical analyses

No statistical analyses for this end point

---

**Primary: Summary of severity of adverse events including serious adverse events**

---

End point title	Summary of severity of adverse events including serious adverse events <sup>[2]</sup>
-----------------	---

End point description:

The occurrence and severity of adverse events would be sought by non-directive questioning of the patient at each visit. Adverse events may also be detected when they are volunteered by the patient during or between visits or through physical examination, laboratory test, or other assessment.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline for duration of study until early termination (04Nov2013)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No additional statistical analyses have been performed for this primary end point.

End point values	AFQ056 25 mg b.i.d.	AFQ056 50 mg b.i.d.	AFQ056 75 mg b.i.d.	AFQ056 100 mg b.i.d.
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18 <sup>[3]</sup>	19 <sup>[4]</sup>	20 <sup>[5]</sup>	50 <sup>[6]</sup>
Units: percentage				
number (not applicable)				
Mild	35	15	45	21.7
Moderate	30	65	45	30.4
Severe	25	15	10	20.3

Notes:

[3] - Patients with any AE

[4] - Patients with any AE

[5] - Patients with any AE

[6] - Patients with any AE

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events are monitored from date of First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All other adverse events are monitored from First Patient First Treatment until Last Patient Last Visit.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	16.1

### Reporting groups

Reporting group title	AFQ056 25 MG
-----------------------	--------------

Reporting group description:

AFQ056 25 MG

Reporting group title	AFQ056 50 MG
-----------------------	--------------

Reporting group description:

AFQ056 50 MG

Reporting group title	AFQ056 75 MG
-----------------------	--------------

Reporting group description:

AFQ056 75 MG

Reporting group title	AFQ056 100 MG
-----------------------	---------------

Reporting group description:

AFQ056 100 MG

Serious adverse events	AFQ056 25 MG	AFQ056 50 MG	AFQ056 75 MG
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 20 (10.00%)	6 / 20 (30.00%)	2 / 20 (10.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
FIBRIN D DIMER INCREASED			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
CERVICAL VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMORAL NECK FRACTURE			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURED SACRUM			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAND FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PELVIC FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RIB FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKULL FRACTURED BASE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TENDON RUPTURE			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ULNA FRACTURE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
HYPOTENSION			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
AKINESIA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSKINESIA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPILEPSY			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FREEZING PHENOMENON			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ISCHAEMIC STROKE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
METABOLIC ENCEPHALOPATHY			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NYSTAGMUS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ON AND OFF PHENOMENON			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARKINSON'S DISEASE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
IRON DEFICIENCY ANAEMIA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
SUDDEN HEARING LOSS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN UPPER			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INGUINAL HERNIA, OBSTRUCTIVE			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DIAPHRAGMATIC RUPTURE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
APATHY			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HALLUCINATION			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
CERVICAL SPINAL STENOSIS			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INTERVERTEBRAL DISC DEGENERATION</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SPINAL COLUMN STENOSIS</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SYNOVIAL CYST</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>HYPOVOLAEMIA</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	AFQ056 100 MG		
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 69 (23.19%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
<b>Investigations</b>			
<b>FIBRIN D DIMER INCREASED</b>			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Injury, poisoning and procedural complications</b>			
<b>CERVICAL VERTEBRAL FRACTURE</b>			

subjects affected / exposed	1 / 69 (1.45%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FEMORAL NECK FRACTURE				
subjects affected / exposed	1 / 69 (1.45%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FEMUR FRACTURE				
subjects affected / exposed	1 / 69 (1.45%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FRACTURED SACRUM				
subjects affected / exposed	1 / 69 (1.45%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
HAND FRACTURE				
subjects affected / exposed	0 / 69 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HUMERUS FRACTURE				
subjects affected / exposed	1 / 69 (1.45%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PELVIC FRACTURE				
subjects affected / exposed	1 / 69 (1.45%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
RIB FRACTURE				
subjects affected / exposed	2 / 69 (2.90%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
SKULL FRACTURED BASE				

subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TENDON RUPTURE</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ULNA FRACTURE</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Vascular disorders</b>			
<b>HYPOTENSION</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
<b>MYOCARDIAL INFARCTION</b>			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
<b>AKINESIA</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DYSKINESIA</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>EPILEPSY</b>			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

FREEZING PHENOMENON	subjects affected / exposed	0 / 69 (0.00%)		
	occurrences causally related to treatment / all	0 / 0		
	deaths causally related to treatment / all	0 / 0		
ISCHAEMIC STROKE	subjects affected / exposed	1 / 69 (1.45%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
METABOLIC ENCEPHALOPATHY	subjects affected / exposed	0 / 69 (0.00%)		
	occurrences causally related to treatment / all	0 / 0		
	deaths causally related to treatment / all	0 / 0		
NYSTAGMUS	subjects affected / exposed	1 / 69 (1.45%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
ON AND OFF PHENOMENON	subjects affected / exposed	2 / 69 (2.90%)		
	occurrences causally related to treatment / all	0 / 2		
	deaths causally related to treatment / all	0 / 0		
PARKINSON'S DISEASE	subjects affected / exposed	1 / 69 (1.45%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders				
IRON DEFICIENCY ANAEMIA	subjects affected / exposed	1 / 69 (1.45%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders				
SUDDEN HEARING LOSS	subjects affected / exposed	0 / 69 (0.00%)		
	occurrences causally related to treatment / all	0 / 0		
	deaths causally related to treatment / all	0 / 0		

Gastrointestinal disorders			
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
INGUINAL HERNIA, OBSTRUCTIVE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
DIAPHRAGMATIC RUPTURE			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DYSPNOEA			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
APATHY			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HALLUCINATION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
CERVICAL SPINAL STENOSIS			

subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INTERVERTEBRAL DISC DEGENERATION</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SPINAL COLUMN STENOSIS</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SYNOVIAL CYST</b>			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Metabolism and nutrition disorders</b>			
<b>HYPOVOLAEMIA</b>			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	AFQ056 25 MG	AFQ056 50 MG	AFQ056 75 MG
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 20 (90.00%)	18 / 20 (90.00%)	20 / 20 (100.00%)
<b>Vascular disorders</b>			
<b>CIRCULATORY COLLAPSE</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
<b>DEEP VEIN THROMBOSIS</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
<b>HYPERTENSION</b>			

subjects affected / exposed	0 / 20 (0.00%)	2 / 20 (10.00%)	2 / 20 (10.00%)
occurrences (all)	0	3	2
HYPOTENSION			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	2
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	2 / 20 (10.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	3	0	0
RAYNAUD'S PHENOMENON			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
THROMBOPHLEBITIS SUPERFICIAL			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	1 / 20 (5.00%)
occurrences (all)	1	1	1
DEVICE DISLOCATION			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
FATIGUE			
subjects affected / exposed	2 / 20 (10.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	2	0	1
GAIT DISTURBANCE			
subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	1	1	0
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
PYREXIA			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
DYSPHONIA			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
DYSPNOEA			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 20 (10.00%) 2	1 / 20 (5.00%) 1
PULMONARY ARTERIAL HYPERTENSION			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
PULMONARY EMBOLISM			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
RESPIRATORY DISTRESS			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
Psychiatric disorders			
ABNORMAL DREAMS			
subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	2 / 20 (10.00%) 2	1 / 20 (5.00%) 1
ANXIETY			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1
APATHY			
subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 20 (5.00%) 1	1 / 20 (5.00%) 1
COMPULSIVE SHOPPING			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1
CONFUSIONAL STATE			
subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3	3 / 20 (15.00%) 4	3 / 20 (15.00%) 3
DELIRIUM			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
DEPRESSED MOOD			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
DEPRESSION			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	2 / 20 (10.00%)
occurrences (all)	0	0	2
HALLUCINATION, AUDITORY			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
HALLUCINATION, VISUAL			
subjects affected / exposed	3 / 20 (15.00%)	5 / 20 (25.00%)	4 / 20 (20.00%)
occurrences (all)	6	6	4
ILLUSION			
subjects affected / exposed	1 / 20 (5.00%)	4 / 20 (20.00%)	3 / 20 (15.00%)
occurrences (all)	1	5	3
INSOMNIA			
subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	2 / 20 (10.00%)
occurrences (all)	1	1	2
LIBIDO INCREASED			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
NIGHTMARE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
RAPID EYE MOVEMENTS SLEEP ABNORMAL			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
SLEEP DISORDER			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	1 / 20 (5.00%)
occurrences (all)	0	1	1
Investigations			
AMYLASE INCREASED			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
BLOOD PRESSURE INCREASED			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	1	0	1
BLOOD TRIGLYCERIDES INCREASED			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
CARDIAC MURMUR			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
HAEMATOCRIT DECREASED			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
HAEMOGLOBIN DECREASED			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
RED BLOOD CELL COUNT DECREASED			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
WEIGHT DECREASED			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
BONE CONTUSION			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
EXCORIATION			
subjects affected / exposed	0 / 20 (0.00%)	2 / 20 (10.00%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
FALL			
subjects affected / exposed	1 / 20 (5.00%)	4 / 20 (20.00%)	2 / 20 (10.00%)
occurrences (all)	1	8	2
HAND FRACTURE			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
HEAD INJURY			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
PERIORBITAL HAEMATOMA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
THERMAL BURN			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
WOUND			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
CONDUCTION DISORDER			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
DIASTOLIC DYSFUNCTION			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
PALPITATIONS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
Nervous system disorders			
AKINESIA			
subjects affected / exposed	5 / 20 (25.00%)	1 / 20 (5.00%)	1 / 20 (5.00%)
occurrences (all)	6	1	2
BRADYKINESIA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	2 / 20 (10.00%)
occurrences (all)	0	0	3
COGNITIVE DISORDER			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
DISTURBANCE IN ATTENTION			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
DIZZINESS			
subjects affected / exposed	2 / 20 (10.00%)	2 / 20 (10.00%)	1 / 20 (5.00%)
occurrences (all)	3	2	1
DYSKINESIA			
subjects affected / exposed	0 / 20 (0.00%)	3 / 20 (15.00%)	2 / 20 (10.00%)
occurrences (all)	0	4	3
FREEZING PHENOMENON			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	1 / 20 (5.00%)
occurrences (all)	0	1	1
HEADACHE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
HYPOAESTHESIA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
HYPOKINESIA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	2 / 20 (10.00%)
occurrences (all)	0	1	2
NERVE COMPRESSION			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
ON AND OFF PHENOMENON			
subjects affected / exposed	1 / 20 (5.00%)	3 / 20 (15.00%)	4 / 20 (20.00%)
occurrences (all)	1	3	4
PARAESTHESIA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
POOR QUALITY SLEEP			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
PRESYNCOPE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
PSYCHOMOTOR HYPERACTIVITY			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1
RESTING TREMOR subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0
SCIATICA subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1
SOMNOLENCE subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	3 / 20 (15.00%) 3	1 / 20 (5.00%) 2
TREMOR subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
VIBRATORY SENSE INCREASED subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
Ear and labyrinth disorders TINNITUS subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0
VERTIGO subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0
Eye disorders VISION BLURRED subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 20 (5.00%) 1	2 / 20 (10.00%) 2
VISUAL IMPAIRMENT subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0	1 / 20 (5.00%) 1
Gastrointestinal disorders ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	0 / 20 (0.00%) 0
CONSTIPATION			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	1 / 20 (5.00%)
occurrences (all)	0	1	1
DENTAL CARIES			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
DIARRHOEA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
DYSPHAGIA			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
GASTRITIS			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
NAUSEA			
subjects affected / exposed	0 / 20 (0.00%)	2 / 20 (10.00%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
VOMITING			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
ERYTHEMA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
NIGHT SWEATS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
RASH			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
Renal and urinary disorders			
INCONTINENCE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
URGE INCONTINENCE			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	1 / 20 (5.00%)	2 / 20 (10.00%)	0 / 20 (0.00%)
occurrences (all)	1	3	0
BACK PAIN			
subjects affected / exposed	2 / 20 (10.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	2	1	0
JOINT SWELLING			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
MOBILITY DECREASED			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
MUSCLE RIGIDITY			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
MUSCLE SPASMS			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	1	0	1
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	1	1	0
OSTEOARTHRITIS			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	1 / 20 (5.00%)
occurrences (all)	0	1	1
PAIN IN EXTREMITY			

subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
POLYARTHRITIS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
Infections and infestations			
EAR INFECTION			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
NASOPHARYNGITIS			
subjects affected / exposed	2 / 20 (10.00%)	1 / 20 (5.00%)	2 / 20 (10.00%)
occurrences (all)	2	1	2
PURULENT DISCHARGE			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
RHINITIS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
TOOTH ABSCESS			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	2	0	1
Metabolism and nutrition disorders			
DEHYDRATION			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
GOUT			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
HYPERCHOLESTEROLAEMIA			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	1	0	1
HYPOCALCAEMIA			

subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
HYPONATRAEMIA			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
INCREASED APPETITE			
subjects affected / exposed	0 / 20 (0.00%)	0 / 20 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	0	1
VITAMIN B12 DEFICIENCY			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0

<b>Non-serious adverse events</b>	AFQ056 100 MG		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	46 / 69 (66.67%)		
Vascular disorders			
CIRCULATORY COLLAPSE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HYPERTENSION			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
HYPOTENSION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	3		
RAYNAUD'S PHENOMENON			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
THROMBOPHLEBITIS SUPERFICIAL			

subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
DEVICE DISLOCATION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
FATIGUE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
GAIT DISTURBANCE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PYREXIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
DYSPHONIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
DYSPNOEA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PULMONARY ARTERIAL HYPERTENSION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PULMONARY EMBOLISM			

subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
RESPIRATORY DISTRESS			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
ABNORMAL DREAMS			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	2		
ANXIETY			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
APATHY			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
COMPULSIVE SHOPPING			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
CONFUSIONAL STATE			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	3		
DELIRIUM			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
DEPRESSED MOOD			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
DEPRESSION			
subjects affected / exposed	3 / 69 (4.35%)		
occurrences (all)	3		
HALLUCINATION, AUDITORY			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HALLUCINATION, VISUAL			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	2		

ILLUSION			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	2		
INSOMNIA			
subjects affected / exposed	4 / 69 (5.80%)		
occurrences (all)	4		
LIBIDO INCREASED			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
NIGHTMARE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
RAPID EYE MOVEMENTS SLEEP ABNORMAL			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
SLEEP DISORDER			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
Investigations			
AMYLASE INCREASED			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
BLOOD PRESSURE INCREASED			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
BLOOD TRIGLYCERIDES INCREASED			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
CARDIAC MURMUR			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HAEMATOCRIT DECREASED			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HAEMOGLOBIN DECREASED			

subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
RED BLOOD CELL COUNT DECREASED			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
WEIGHT DECREASED			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	2		
Injury, poisoning and procedural complications			
BONE CONTUSION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
EXCORIATION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
FALL			
subjects affected / exposed	6 / 69 (8.70%)		
occurrences (all)	9		
HAND FRACTURE			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
HEAD INJURY			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PERIORBITAL HAEMATOMA			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
THERMAL BURN			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
WOUND			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
Cardiac disorders			

CONDUCTION DISORDER subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
DIASTOLIC DYSFUNCTION subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
PALPITATIONS subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1		
Nervous system disorders			
AKINESIA subjects affected / exposed occurrences (all)	3 / 69 (4.35%) 3		
BRADYKINESIA subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1		
COGNITIVE DISORDER subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
DISTURBANCE IN ATTENTION subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
DIZZINESS subjects affected / exposed occurrences (all)	6 / 69 (8.70%) 11		
DYSKINESIA subjects affected / exposed occurrences (all)	13 / 69 (18.84%) 17		
FREEZING PHENOMENON subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
HEADACHE subjects affected / exposed occurrences (all)	3 / 69 (4.35%) 3		
HYPOAESTHESIA			

subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HYPOKINESIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
NERVE COMPRESSION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
ON AND OFF PHENOMENON			
subjects affected / exposed	6 / 69 (8.70%)		
occurrences (all)	7		
PARAESTHESIA			
subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	2		
POOR QUALITY SLEEP			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PRESYNCOPE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PSYCHOMOTOR HYPERACTIVITY			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
RESTING TREMOR			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
SCIATICA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
SOMNOLENCE			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		
TREMOR			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	2		
VIBRATORY SENSE INCREASED			

subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
Ear and labyrinth disorders TINNITUS subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
VERTIGO subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 2		
Eye disorders VISION BLURRED subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 2		
VISUAL IMPAIRMENT subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1		
Gastrointestinal disorders ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)	2 / 69 (2.90%) 2		
CONSTIPATION subjects affected / exposed occurrences (all)	5 / 69 (7.25%) 5		
DENTAL CARIES subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
DIARRHOEA subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
DYSPHAGIA subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1		
GASTRITIS subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0		
NAUSEA			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>VOMITING</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 69 (4.35%)</p> <p>3</p> <p>2 / 69 (2.90%)</p> <p>2</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>ERYTHEMA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>NIGHT SWEATS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>RASH</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 69 (0.00%)</p> <p>0</p> <p>1 / 69 (1.45%)</p> <p>1</p> <p>1 / 69 (1.45%)</p> <p>1</p>		
<p>Renal and urinary disorders</p> <p>INCONTINENCE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>URGE INCONTINENCE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 69 (0.00%)</p> <p>0</p> <p>0 / 69 (0.00%)</p> <p>0</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>ARTHRALGIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BACK PAIN</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>JOINT SWELLING</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>LUMBAR SPINAL STENOSIS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>MOBILITY DECREASED</p>	<p>2 / 69 (2.90%)</p> <p>2</p> <p>2 / 69 (2.90%)</p> <p>3</p> <p>0 / 69 (0.00%)</p> <p>0</p> <p>0 / 69 (0.00%)</p> <p>0</p>		

subjects affected / exposed	2 / 69 (2.90%)		
occurrences (all)	2		
MUSCLE RIGIDITY			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
MUSCLE SPASMS			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
OSTEOARTHRITIS			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
PAIN IN EXTREMITY			
subjects affected / exposed	3 / 69 (4.35%)		
occurrences (all)	3		
POLYARTHRITIS			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
Infections and infestations			
EAR INFECTION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
NASOPHARYNGITIS			
subjects affected / exposed	9 / 69 (13.04%)		
occurrences (all)	9		
PURULENT DISCHARGE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
RHINITIS			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		

TOOTH ABSCESS			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
URINARY TRACT INFECTION			
subjects affected / exposed	4 / 69 (5.80%)		
occurrences (all)	6		
Metabolism and nutrition disorders			
DEHYDRATION			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
GOUT			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HYPERCHOLESTEROLAEMIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HYPOCALCAEMIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
HYPONATRAEMIA			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
INCREASED APPETITE			
subjects affected / exposed	0 / 69 (0.00%)		
occurrences (all)	0		
VITAMIN B12 DEFICIENCY			
subjects affected / exposed	1 / 69 (1.45%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 June 2012	<p>The protocol was amended to allow concomitant treatment with amantadine and to collect long-term safety and safety data on concomitant amantadine and AFQ056 in this patient population. Amantadine was frequently used to treat LIDs and permitting concomitant treatment with AFQ056 may provide additional treatment options for these patients. AEs associated with amantadine are similar to AFQ056 (e.g. dizziness, hallucinations, fatigue), and concomitant administration with AFQ056 may increase the likelihood of these AEs. However, these events were expected to be transient and reversible.</p> <p>In addition, the amended protocol, in line with the FDA Guidance on the prospective suicidality assessment in clinical trials, required the C-SSRS to be assessed at every postbaseline visit, including unscheduled visits.</p>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated based on the results of studies CAFQ056A2222 and CAFQ056A2223 (due to lack of efficacy) and the sponsor's decision to terminate the program

Notes: